DALLAS, TX and NEW YORK, NY July 29, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, today announced that it will host a conference call at 11:00 a.m. EDT on August 3rd, to provide an update on the Company’s strategy and activities surrounding the official launch its lead product, MuGard in North America. Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.
Read more »
DALLAS, TX and NEW YORK, NY July 28, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that Zacks Investment Research, has issued a research update summarizing some of the recent positive developments that the Company has been able to achieve which have led to reiteration of the ‘Outperform’ rating on ACCP and a six-twelve month price target of $8.00.
Read more »
DALLAS, TX and NEW YORK, NY July 27, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, today announced its e-marketing partner, iMedicor (OTCBB: VMCI) commenced the initial phase of a multi-channel marketing program for MuGard. iMedicor’s two-pronged marketing approach involves leveraging its direct sales channel through Direct Medical Solutions (DMS) and its online pharma marketing portal to further support Access’ ongoing commercial launch efforts for its lead product. The initial phase of the marketing program for MuGard includes a targeted sampling program to DMS’ physician network.
Read more »
Agreement Provides Multi-level Distribution Of Lead Product, Including Inventory In Over 30 Top Metro Areas
DALLAS, TX and NEW YORK, NY July 20, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has signed an exclusive specialty distribution agreement with BioScrip (Nasdaq: BIOS) for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy. The agreement aligns the Company with comprehensive access to BioScrip’s nationwide distribution platform and the ability to leverage the company’s extensive physician relationships, 110 BioScrip specialty pharmacies, mail distribution capability and diversified payor network.
Read more »
DALLAS, TX and NEW YORK, NY July 15, 2010
Access Pharmaceuticals, Inc. (OTCBB: ACCP), announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs. Access will utilize its proprietary Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing. Although the terms of the agreement have not been disclosed, Access indicated that any successful formulation developed will be subject to a subsequent full-licensing agreement.
Read more »
Dallas, TX, and New York, NY
Below is a video clip of Access Pharmaceuticals’ CEO, Jeffrey B. Davis presenting at the One Med Forum: Emerging Company Finance Conference on Wednesday, June 30th at 9:20 AM ET.
Read more »
Digg!
Del.icio.us
MuGard's ready-to-use viscous liquid is tasteless, and is safe to swallow. See